Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Histologically-confirmed recurrent ovarian, fallopian tube, primary peritoneal cancer,
             endometrial, vaginal, or cervical cancer in the abdomen and pelvis

          -  Subjects with stage IV disease are eligible as long as disease elsewhere (other than
             the site(s) to receive radiation therapy [RT]) is undetectable or stable (>= 3 months)
             and immediate chemotherapy is not required. Willingness to discontinue any cytotoxic
             chemotherapeutic agents, immunotherapy, biologic therapy, and targeted therapies at
             least three weeks prior to start of investigational therapy

          -  Hemoglobin >= 10.0 g/dL and no blood transfusions in the 28 days prior to
             entry/randomization (choose whichever is most applicable to the study) (within 28 days
             prior to administration of study treatment)

          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (within 28 days prior to
             administration of study treatment)

          -  No features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
             on peripheral blood smear (within 28 days prior to administration of study treatment)

          -  White blood cells (WBC) > 3 x 10^9/L (within 28 days prior to administration of study
             treatment)

          -  Platelet count >= 100 x 10^9/L (within 28 days prior to administration of study
             treatment)

          -  Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 28 days
             prior to administration of study treatment)

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 x institutional upper limit of normal unless liver metastases are present in
             which case it must be =< 5 x ULN (within 28 days prior to administration of study
             treatment)

          -  Serum creatinine =< 1.5 x institutional upper limit of normal (ULN) (within 28 days
             prior to administration of study treatment)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

               -  Note: If cannot fulfill ECOG 0-1, must fulfill inclusion criteria below (minimum
                  life expectancy of >= 16 weeks)

          -  Patients must have a life expectancy >= 16 weeks

          -  Evidence of non-childbearing status for women of childbearing potential: negative
             urine or serum pregnancy test within 28 days of study treatment, confirmed prior to
             treatment on day 1. Postmenopausal is defined as:

               -  Amenorrheic for 1 year or more following cessation of exogenous hormonal
                  treatments, luteinizing hormone (LH) and follicle stimulating hormone (FSH)
                  levels in the post menopausal range for women under 50, radiation-induced
                  oophorectomy with last menses > 1 year ago, chemotherapy-induced menopause with >
                  1 year interval since last menses, or surgical sterilization (bilateral
                  oophorectomy or hysterectomy)

          -  Patient of child-bearing potential is willing to adhere to using two forms of highly
             effective birth control. Condoms with spermicide and one of the following are
             acceptable: oral contraceptive or hormonal therapy or placement of an intrauterine
             device (IUD). Acceptable non-hormonal birth control methods include: total sexual
             abstinence, vasectomized sexual partner plus male condom, tubal occlusion plus male
             condom with spermicide, IUD plus male condom+spermicide. Acceptable hormonal methods
             include: etonogestrel implants (i.e. Implanon, Norplan), normal and low dose combined
             oral pills, norelgestromin/ethinyl estradiol (EE) transdermal system, intravaginal
             device (i.e. EE and etonogestrel) or cerazette (desogestrel). All of these would need
             to be combined with male condom with spermicide

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up

          -  At least one lesion, not previously irradiated, that can be accurately measured at
             baseline as >= 10 mm in the longest diameter (except lymph nodes which must have short
             axis >= 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and
             which is suitable for accurate repeated measurements

          -  For inclusion in biomarker endpoint, patients must fulfill the following criterion:

               -  Provision of informed consent for tumor biopsies * If a patient declines to
                  participate in tumor biopsies, there will be no penalty or loss of benefit to the
                  patient. The patient will not be excluded from other aspects of the study
                  described in this Clinical Study Protocol, so long as they consent to that part

        Exclusion Criteria:

          -  Ascites, peritoneal carcinomatosis, hepatic metastases

          -  Prior radiotherapy in the region of planned radiotherapy

          -  Chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other
             investigational agents within the 3 weeks prior to start of therapy

          -  Previous enrollment in the present study

          -  Participation in another clinical study with an investigational product during the
             last 4 weeks

          -  Patients with second primary cancer, except: adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumors
             curatively treated with no evidence of disease for >= 5 years (will require discussion
             with study physician)

          -  Patients receiving any systemic chemotherapy, radiotherapy

          -  Concomitant use of known CYP3A4 inhibitors such as ketoconazole, itraconazole,
             ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir

          -  Concomitant use of known P-gp inhibitors (i.e. dronedarone, quinidine, ranolazine,
             verapamil, ketoconazole, itraconazole), P-glycoprotein (P-gp) inducers (i.e. rifampin,
             tipranavir, ritonavir), or breast cancer resistance protein (BCRP) inhibitors (i.e.
             elacridar [GF120918]) should be avoided. If patients are taking any P-gp inhibitors,
             P-gp inducers, or BRCP inhibitors, they will need to stop them prior to enrolment on
             the study

          -  Persistent toxicities (>= Common Terminology Criteria for Adverse Events [CTCAE] grade
             2) with the exception of alopecia, caused by previous cancer therapy

          -  Resting electrocardiogram (ECG) with corrected QT (QTc) > 470 msec on 2 or more time
             points within a 24 hour period or family history of long QT syndrome

          -  Patients with myelodysplastic syndrome/acute myeloid leukemia

          -  Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence
             of brain metastases is not required. The patient can receive a stable dose of
             corticosteroids before and during the study as long as these were started at least 28
             days prior to treatment

          -  Major surgery within 14 days of starting study treatment and patients must have
             recovered from any effects of any major surgery

          -  Patients considered a poor medical risk due to a serious, uncontrolled medical
             disorder, non-malignant systemic disease or active, uncontrolled infection. Examples
             include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3
             months) myocardial infarction, unstable spinal cord compression (untreated and
             unstable for at least 28 days prior to study entry), superior vena cava syndrome,
             extensive bilateral lung disease on high resolution computed tomography (CT) scan or
             any psychiatric disorder that prohibits obtaining informed consent

          -  Patients unable to swallow orally administered medication and patients with
             gastrointestinal disorders likely to interfere with absorption of the study medication

          -  Breast feeding women

          -  Patients with a known hypersensitivity to talazoparib or any of the excipients of the
             product

          -  Patients with uncontrolled seizures

          -  Patients requiring pelvic and para-aortic radiotherapy (defined as levels L1/T12)

          -  Patients with isolated vaginal relapse (i.e. no disease in lymph nodes or else where
             in pelvis/abdomen)